News | Magnetic Resonance Imaging (MRI) | November 17, 2020

SyntheticMR Announces Submission of 510(k) to FDA for Quantitative MSK MRI Package

A 6-minute scan can now provide multiple contrast images, and 5 quantitative tissue maps for MSK anatomies, including spine, knee, pelvis, ankles and shoulders

SyntheticMR, an innovative software solutions company for magnetic resonance imaging (MRI) announced today the company filed a 510(k) submission for its musculoskeletal solutions package, SyMRI MSK.

November 17, 2020 — SyntheticMR, an innovative software solutions company for magnetic resonance imaging (MRI) announced today the company filed a 510(k) submission for its musculoskeletal solutions package, SyMRI MSK.

“We are thrilled to receive 510(k) pending status for SyMRI MSK,” said Ulrik Harrysson, CEO, SyntheticMR. “In today’s environment, there is a clear demand for quantitative solutions in the musculoskeletal market and we believe that we have a unique opportunity to enable physicians to make better, more informed decisions using quantitative imaging in MSK applications.”

Like its neuro counterpart, the SyMRI MSK package provides radiologists a solution-based approach by offering 6-minute scans that can drastically improve patient throughput, produce a range of contrast-weight­ed images, as well as quantitative T1, T2, and PD maps for both clinical and research practices for all MSK anatomies and joints – including spine.

“Most people will experience joint or back pain at some point of their lives,” explains Kyle Frye, President of SyntheticMR US. “While it’s routine to use MRI to help physicians diagnose issues relative to the knee, shoulder, ankle, and spine, now we are taking it to the next level by providing a quantitative approach. In other words, we’re helping move from a subjective environment to one that is objective. And that’s something we are truly excited about.”

SyMRI MSK uses a unique scanning sequence to measure the ab­solute properties of the anatomy and joins the SyntheticMR’s growing portfolio of quantitative software solutions, which includes SyMRI NEURO.

For more information: www.syntheticmr.com

Related Content

Chest X-ray image of patient with lung injury due to vaping. Image courtesy of UC Regents #COVID19 #pandemic

Chest X-ray image of patient with lung injury due to vaping. Image courtesy of UC Regents

News | Coronavirus (COVID-19) | November 19, 2020
November 19, 2020 — A UC Davis Health ped
1H-MR spectra of 3 consecutive patients with COVID-19. Upper row: Axial FLAIR images at the corona radiata level show representative MRS voxels (black squares) from sampled periventricular regions. Lower row: Corresponding spectrum (black) and LCModel fit (red) from each patient acquired at TE = 30 ms (upper row) and TE = 288 ms (lower row). A, A patient with COVID-19-associated multifocal necrotizing leukoencephalopathy shows diffuse patchy WM lesions with markedly increased Cho and decreased NAA, as well

1H-MR spectra of 3 consecutive patients with COVID-19. Upper row: Axial FLAIR images at the corona radiata level show representative MRS voxels (black squares) from sampled periventricular regions. Lower row: Corresponding spectrum (black) and LCModel fit (red) from each patient acquired at TE = 30 ms (upper row) and TE = 288 ms (lower row). A, A patient with COVID-19-associated multifocal necrotizing leukoencephalopathy shows diffuse patchy WM lesions with markedly increased Cho and decreased NAA, as well as elevated Lac. B, A patient with COVID-19 after recent PEA cardiac arrest with subtle FLAIR hyperintense white matter changes also shows elevated Cho/Cr and decreased NAA/Cr ratios. However, these derangements are less severe than in the patient in A. There is no clear elevation of Lac. C, A patient with COVID-19 without encephalopathy or recent severe hypoxia has normal Cho/Cr, with mildly decreased NAA/Cr and no lactate elevation. Cho, Choline; NAA, N-Acetyl-Aspartate; mI, Myo-Inositol; Lac, Lactate; Glx, Glutamate + Glutamine. Image courtesy of AJNR

News | Coronavirus (COVID-19) | November 19, 2020
November 19, 2020 — One of the first spectroscopic imaging-based studies of neurological injury in...
Reduces the complexity of reporting for screening and diagnostic MRI eams to deliver time-saving and patient safety benefits
News | MRI Breast | November 18, 2020
November 18, 2020 — ...